Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDP · 1 trial · 3 indications
CR rate is defined as proportion of subjects with a CR based on the Lugano Criteria 2022 following 3 cycles of combination treatment.
| Arm | Type | Description |
|---|---|---|
| GDP + Epcoritamab + AutoSCT or CAR T-cell therapy | EXPERIMENTAL | Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15. Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritamab will administered at 48mg on Days 1, 8 and 15 Gemcitabine will be administered by IV infusion on Days 1 and 8. Gemcitabine Days 1,8: 1,000mg/m\^2 Cisplatin will be administered by IV infusion on Day 1. Cisplatin Day 1: 75mg/m\^2 Dexamethasone will be given by mouth on Days 1-4. Dexamethasone Days 1-4: 40mg After completion of Cycle 3 Autologous stem cell transplant (AutoSCT) OR CAR T-cell therapy |
| GDP + Epcoritamab + Epcoritamab Maintenance | EXPERIMENTAL | Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15 of each Cycle. Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritabab will administered at 48mg on Days 1, 8 and 15 Gemcitabine will be administered by IV infusion on Days 1 and 8 of each Cycle. Gemcitabine Days 1,8: 1,000mg/m\^2 Cisplatin will be administered by IV infusion on Day 1 of each Cycle. Cisplatin Day 1: 75mg/m\^2 Dexamethasone will be given by mouth on Days 1-4 of Cycle 1 ONLY. Dexamethasone Days 1-4: 40mg Cycles 4-9 (Cycle =28 Days) Epcoritamab will be administered by subcutaneous injection on Days 1, 8, and 15 of Cycles 4-9. |
| Name | Type | Description |
|---|---|---|
| AutoSCT OR CAR T-cell Therapy | PROCEDURE | Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP |
| GDP | DRUG | Gemcitabine Cisplatin Dexamethasone |
| Epcoritamab | DRUG | Epcoritamab |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent. 3. ECOG Performance Status of...
GDP is a combination salvage chemotherapy regimen being studied for relapsed or refractory large B-cell lymphoma. It is being evaluated in a Phase 2 clinical trial in combination with epcoritamab, an investigational therapy, for patients with diffuse large B-cell lymphoma that has relapsed or is refractory to prior treatment.
GDP is being studied by Genmab A/S, a biopharmaceutical company listed on the Nasdaq under the ticker GMAB. The company is sponsoring a Phase 2 clinical trial that evaluates the safety and efficacy of GDP when combined with epcoritamab in patients with relapsed or refractory large B-cell lymphoma.
GDP is in Phase 2 clinical development. It is being evaluated in an ongoing, recruiting Phase 2 trial (NCT05852717) that combines GDP with epcoritamab for the treatment of relapsed or refractory large B-cell lymphoma. The trial is enrolling adult patients in the United States.
GDP is being studied in one active Phase 2 clinical trial, NCT05852717, titled 'Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma.' The trial is recruiting 32 participants in the United States and is not randomized or double-blinded.
GDP is investigational and not FDA approved for the treatment of large B-cell lymphoma. It is currently in Phase 2 clinical development, with an active trial evaluating its safety and efficacy in combination with epcoritamab for patients with relapsed or refractory disease.